• Clinical Trials Adrift in the Age of Social Media

    Jun 13 | Clinical Research News | Many forces outside of the healthcare setting shape people’s decisions about whether to join or stay in a clinical trial or comply with study-related requirements. While no strong evidence exists that influencers on social media are impacting the integrity of trials, it has become self-evident that they have the power to undermine the authority of traditional sources of information and their sway is therefore an issue “very deserving of our attention." More
  • Watching the State of Clinical Trial Data Compliance

    Jun 11 | Clinical Research News | Until relatively recently, clinical-trial submissions in the EU had to be made separately to each applicable member-state’s authority. The process was inefficient and laborious, resulting in a lot of complaints from clinical-research organizations. On January 31, 2022, the EU Clinical Trials Regulation came into effect. More
  • ‘Continuity’ and Why It’s Now Critical for Successful Ophthalmic Clinical Trials

    Jun 07 | Clinical Research News | Ophthalmic clinical trials are expanding in global reach, incorporating a wide range of geographical areas, sites, personnel, and imaging technologies. Maintaining data integrity, imaging reliability, process efficiency, and regulatory compliance across these multi-faceted environments can be quite challenging—and is why continuity across image collection, processing, and management is now a fundamental “must-have” for ophthalmic clinical trial success. More
  • AI Model Estimates Treatment Effect on Par With Clinical Trials

    Jun 06 | Clinical Research News | Researchers at The Ohio State University (OSU) have been using artificial intelligence (AI) for several years now to emulate clinical trials by crunching real-world data (RWD). In their latest computational feat, they succeeded in precisely estimating results of randomized clinical trials comparing the effectiveness of two treatments for reducing the risk of stroke after coronary artery disease. More
  • Blood Test Could Improve Diagnosis of Severe Strokes on a Global Scale

    Jun 04 | Clinical Research News | Researchers at The Ohio State University (OSU) have been using artificial intelligence (AI) for several years now to emulate clinical trials by crunching real-world data (RWD). In their latest computational feat, they succeeded in precisely estimating results of randomized clinical trials comparing the effectiveness of two treatments for reducing the risk of stroke after coronary artery disease. More
  • American Clinical Research Services Acquires Elixia, Oxford BioDynamics, King’s College London Collaborate, Recursion’s Supercomputer Ranked, More

    May 29 | Clinical Research News | American Clinical Research Services has acquired Elixia; Oxford BioDynamics and King's College London are teaming up in the immediate follow up of the APIPPRA trial, the largest RA prevention trial to date; Recursion’s BioHive-2 was dubbed No. 35 on the latest TOP500 list of the world’s fastest supercomputers; more. More
  • Follow the Money: Blackstone Launches Portfolio Company, PCORI Approves Funds for CER Studies, Funds Gifted for Alzheimer’s Research, More

    May 28 | Clinical Research News | Blackstone launches the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation; the Patient-Centered Outcomes Research Institute secures approval of funding awards to support new patient-centered comparative clinical effectiveness research studies; Laurence Belfer gifts funds to the University of Texas MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium, a transformative multi-institutional initiative to advance the study and treatment of Alzheimer’s disease; more. More
  • The Risk-Based Data Management (RBDM) Revolution

    May 24 | Clinical Research News | The clinical trials landscape is evolving with more data, increased investment in personalized medicines and a shift toward decentralized and hybrid clinical trials. At the same time, the industry is attempting to become more efficient and harness new technologies and data science in operations. More
  • Pan-RAS Inhibitor Offers Hope of Improved Pancreatic Cancer Prognosis

    May 22 | Clinical Research News | A consortium of pancreatic cancer researchers sharing information in real time has shown that an oral pan-RAS inhibitor known as RMC-7977, developed by Revolution Medicines, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells—and did so across a comprehensive range of preclinical models in a series of similar experiments. More
  • Brain Stimulation Device Could Make Precision Mental Health A Reality

    May 21 | Clinical Research News | In the not-too-distant future, disorders of the brain could be treated with the same precision as heart disease and cancer. The means will be a therapeutic brain-computer interface (BCI) the size of a small blueberry for people suffering from treatment-resistant depression that uses a similar type of implant technology as Elon Musk’s Neuralink for helping paralyzed people speak. More
View more articles
 
DXX-Industry-spotlight
SOT

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News Senior writer Deborah Borfitz welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.